Even with the clinical success seen with cell therapies, they are not sufficient as a regenerative strategy. In particular, we have observed inefficient cell survival and growth in injured tissue environments such as cardiac infarction and osteochondral lesions. Accordingly, medical device and biopharma companies are beginning to recognize the renewed potential for tissue engineering.
We are at a unique moment in time in which advances in cellular biology, manufacturing, and biomaterials are converging. This convergence has created an opportunity to dramatically improve the way we design and manufacture products for tissue repair and regeneration. Utilizing these new tools, tissue engineers can design for both biofunctionality and manufacturability – and their interdependencies.
Form designed for function
It is generally accepted that what an implant is made of (composition) and how porous it is (microstructure) are critical for tissue remodeling and regeneration. A growing body of evidence demonstrates the importance of the cellular microenvironment and the ability to alter cell behavior by controlling that microenvironment. The challenge is engineering a product that is capable of providing the right cues at the same time to generate the desired biological response – and doing it in a way that is affordable and scalable.
For instance, in bone repair, hydroxyapatite granules have long been used to patch defects. Why? Because that’s what our bones are made of. Our cells can react intimately with the granules and remodel them over time as they would do with natural bone. However, just placing a block of solid hydroxyapatite in a bony defect is not going to regenerate bone.
That’s where microstructure comes into play. For example, we know that porosity is important. That’s why we see porous titanium now for orthopedic applications. Cells and eventually tissue infiltrate the implant through the pores and anchor it more tightly in place. Again, there’s a greater intimacy between the product and our natural tissue. However, with titanium or plastic, that intimacy is all that happens. The tissue doesn’t actually remodel because the composition is not right. Further, the porosity in this case is limited to the architecture, not to the material itself.
Today, new systems are emerging that allow product development engineers and scientists to design regenerative constructs with the precise interplay among a number influential factors – biochemical, structural, mechanical, and more – to achieve the desired function.
Architecting the microenvironment
By designing regenerative microenvironments, the construct itself provides the necessary instructions to surrounding or incorporated cells that promote the desired biological response such as cell infiltration, matrix deposition, and new blood vessel formation.
To achieve such regenerative templates, engineers must be empowered with the necessary design and manufacturing tools. This is what’s changing in the industry. For 30 years, tissue engineers have had a limited set of tools, but today we have new ways of controlling the three-dimensional microenvironment. 3D-printing allows for the spatial organization of material and cells to create more complex and reproducible artificial environments that may lead to better biological outcomes.
At the core, this requires access to a broad range of biomaterials that can be architected and tuned to create the ideal microenvironment for regeneration. Composition and structure cannot be limited to the inherent properties of a single source biomaterial. Plus, the construct must contain or be compatible with bioactive factors, e.g., growth factors, extracellular proteins, and cells, that can provide the right cellular signaling.
Such constructs need to be designed to have structural integrity yet be agile enough to integrate with and adapt to the body’s dynamic environment. They must hold shape but also exhibit the right porosity, pore size and shape, and degradation profile. Moreover, multi-level porosity is key, such that there are pores within the material fibers themselves at the micro- and nano-scale. Creating the ideal microenvironment will likely require multiple materials working in concert with each other, particularly for more complex tissues.
When all the necessary features align, only then can these constructs promote tissue restoration. Of course, this approach does not minimize the importance of cells. In fact, one could argue that this approach is designed specifically for cells. Whether seeding cells into a construct, printing cells, or relying on interaction with endogenous cells, ultimate healing results when the right interplay is at work such that cells self-organize and remodel the temporary regenerative template into viable long-lasting tissues.
A step closer to commercialization?
This materials-centric approach offers promise for the future commercialization of regenerative medical products. Beyond the technical advantages, it may also facilitate regulatory and manufacturing strategies that can overcome challenges restraining the field (see https://3dprint.com/275909/three-key-hurdles-restraining-the-growth-of-the-tissue-engineering-field/).
If regenerative “templates” can be reproducibly manufactured from materials already deemed safe by regulatory agencies, and not hampered by the limitations of cell expansion or the need to develop and test novel engineering hardware, perhaps an avenue exists to accelerate the commercial development of TEMPs.
You May Also Like
3DPOD Episode 61: Cold Spray Metal Printing with Byron Kennedy, SPEE3D CEO
Byron Kennedy is the CEO of SPEE3D, an Australian firm that develops cold spray metal 3D printing. After a successful exit in powertrain components, he and his business partner Steven...
3DPOD Episode 60: AM Metal Powder Production with MolyWorks CEO Chris Eonta
This episode is a blast, as we descend into the mayhem that was the early days of MolyWorks. A team that tries to make a gas atomizer on a founder’s...
Stratasys Reveals Three New Systems with Three Different 3D Printing Technologies for End-Use Parts
Last month, Stratasys (NASDAQ: SSYS) announced that it was releasing its new H Series Production Platform line of printers, based on powder bed fusion (PBF) technology, or, more specifically, its industrial-grade...
3DPOD Episode 59: PostProcess CEO Jeff Mize
Jeff Mize is a veteran entrepreneur who sold his firm NAVTEQ to Nokia for $8.1 billion and his Climate Corporation to Monsanto for $1.1 billion. He now heads up PostProcess...
View our broad assortment of in house and third party products.